Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Obesity
- Overweight
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Sponsor staff involved in the clinical trial is masked according to company standard proceduresPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 45 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03574597
- Collaborators
- Not Provided
- Investigators
- Study Director: Clinical Reporting Anchor and Disclosure (1452) Novo Nordisk A/S